Jun 24 |
What's Going On With Regulus Therapeutics Stock Monday?
|
Jun 24 |
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Jun 14 |
Regulus Therapeutics Inc.'s (NASDAQ:RGLS) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
|
Jun 4 |
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
|
May 16 |
Regulus Therapeutics names Rekha Garg as chief medical officer
|
May 16 |
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
|
May 9 |
Regulus Therapeutics GAAP EPS of -$0.29
|
May 9 |
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
|
May 7 |
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
|
May 6 |
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|